# Innoviva, Inc.: financial statements, quarterly

INVA · Nasdaq · CIK 1080014 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/inva.md) · [Financials](/companies/inva/financials.md) · [Filings](/companies/inva/filings.md) · [Insiders](/companies/inva/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/inva/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [67.3](/filings/0000950170-24-122375.md) | [85.8 d](/filings/0001193125-26-071776.md) | [77.5](/filings/0000950170-25-065765.md) | [99.9](/filings/0000950170-25-104126.md) | [89.5](/filings/0001193125-25-267040.md) | [91.8 d](/filings/0001193125-26-071776.md) | [88.6](/filings/0001193125-26-209110.md) | [100](/filings/0001193125-26-335235.md) | [108](/filings/0001193125-25-267040.md) | [115 d](/filings/0001193125-26-071776.md) | [98.0](/filings/0001193125-26-209110.md) | [120](/filings/0001193125-26-335235.md) |
| Cost of revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Gross profit | $m | not reported | not reported | [60.1](/filings/0000950170-25-065765.md) | [85.0](/filings/0000950170-25-104126.md) | [73.0](/filings/0001193125-25-267040.md) | [78.1 d](/filings/0001193125-26-071776.md) | [73.3](/filings/0001193125-26-209110.md) | [83.1](/filings/0001193125-26-335235.md) | [75.5](/filings/0001193125-25-267040.md) | [75.7 d](/filings/0001193125-26-071776.md) | [75.8](/filings/0001193125-26-209110.md) | [90.6](/filings/0001193125-26-335235.md) |
| Research and development | $m | [4.0](/filings/0000950170-24-122375.md) | [2.4 d](/filings/0001193125-26-071776.md) | [3.9](/filings/0000950170-25-065765.md) | [2.6](/filings/0000950170-25-104126.md) | [3.6](/filings/0001193125-25-267040.md) | [3.7 d](/filings/0001193125-26-071776.md) | [4.4](/filings/0001193125-26-209110.md) | [8.0](/filings/0001193125-26-335235.md) | [13.7](/filings/0001193125-25-267040.md) | [4.6 d](/filings/0001193125-26-071776.md) | [5.2](/filings/0001193125-26-209110.md) | [5.2](/filings/0001193125-26-335235.md) |
| Selling, general and administrative | $m | [28.6](/filings/0000950170-24-122375.md) | [26.3 d](/filings/0001193125-26-071776.md) | [30.4](/filings/0000950170-25-065765.md) | [27.7](/filings/0000950170-25-104126.md) | [26.2](/filings/0001193125-25-267040.md) | [31.3 d](/filings/0001193125-26-071776.md) | [27.5](/filings/0001193125-26-209110.md) | [26.4](/filings/0001193125-26-335235.md) | [27.3](/filings/0001193125-25-267040.md) | [32.1 d](/filings/0001193125-26-071776.md) | [32.4](/filings/0001193125-26-209110.md) | [34.6](/filings/0001193125-26-335235.md) |
| Operating income | $m | not reported | not reported | [25.8](/filings/0000950170-25-065765.md) | [54.7](/filings/0000950170-25-104126.md) | [43.2](/filings/0001193125-25-267040.md) | [43.1 d](/filings/0001193125-26-071776.md) | [41.4](/filings/0001193125-26-209110.md) | [48.8](/filings/0001193125-26-335235.md) | [34.6](/filings/0001193125-25-267040.md) | [39.0 d](/filings/0001193125-26-071776.md) | [38.2](/filings/0001193125-26-209110.md) | [50.9](/filings/0001193125-26-335235.md) |
| Interest expense | $m | [4.4](/filings/0000950170-24-122375.md) | [6.0 d](/filings/0001193125-26-071776.md) | [5.9](/filings/0000950170-25-065765.md) | [5.8](/filings/0000950170-25-104126.md) | [5.8](/filings/0001193125-25-267040.md) | [4.7 d](/filings/0001193125-26-071776.md) | [4.7](/filings/0001193125-26-209110.md) | [4.7](/filings/0001193125-26-335235.md) | [4.0](/filings/0001193125-25-267040.md) | [3.3 d](/filings/0001193125-26-071776.md) | [5.4](/filings/0001193125-26-209110.md) | [5.5](/filings/0001193125-26-335235.md) |
| Income tax | $m | [3.9](/filings/0000950170-24-122375.md) | [(0.3) d](/filings/0001193125-26-071776.md) | [8.6](/filings/0000950170-25-065765.md) | [(4.6)](/filings/0000950170-25-104126.md) | [5.6](/filings/0001193125-25-267040.md) | [4.4 d](/filings/0001193125-26-071776.md) | [8.0](/filings/0001193125-26-209110.md) | [8.9](/filings/0001193125-26-335235.md) | [7.9](/filings/0001193125-25-267040.md) | [30.9 d](/filings/0001193125-26-071776.md) | [48.0](/filings/0001193125-26-209110.md) | [(24.6)](/filings/0001193125-26-335235.md) |
| Net income | $m | [82.0](/filings/0000950170-24-122375.md) | [61.5 d](/filings/0001193125-26-071776.md) | [36.5](/filings/0001193125-25-267040.md) | [(34.7)](/filings/0001193125-25-267040.md) | [1.2](/filings/0001193125-25-267040.md) | [20.3 d](/filings/0001193125-26-071776.md) | [(46.6)](/filings/0001193125-26-335235.md) | [63.7](/filings/0001193125-26-335235.md) | [89.9](/filings/0001193125-25-267040.md) | [164 d](/filings/0001193125-26-071776.md) | [187](/filings/0001193125-26-335235.md) | [(83.4)](/filings/0001193125-26-335235.md) |
| Diluted EPS | $ per share | [0.98](/filings/0000950170-24-122375.md) | not reported | [0.46](/filings/0000950170-25-065765.md) | [(0.55)](/filings/0000950170-25-104126.md) | [0.02](/filings/0001193125-25-267040.md) | not reported | [(0.74)](/filings/0001193125-26-209110.md) | [0.77](/filings/0001193125-26-335235.md) | [1.08](/filings/0001193125-25-267040.md) | not reported | [2.22](/filings/0001193125-26-209110.md) | [(1.14)](/filings/0001193125-26-335235.md) |
| Basic EPS | $ per share | [1.26](/filings/0000950170-24-122375.md) | not reported | [0.58](/filings/0000950170-25-065765.md) | [(0.55)](/filings/0000950170-25-104126.md) | [0.02](/filings/0001193125-25-267040.md) | not reported | [(0.74)](/filings/0001193125-26-209110.md) | [1.01](/filings/0001193125-26-335235.md) | [1.30](/filings/0001193125-25-267040.md) | not reported | [2.52](/filings/0001193125-26-209110.md) | [(1.14)](/filings/0001193125-26-335235.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: not reported
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:ProfitLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [180](/filings/0000950170-23-057530.md) | [194](/filings/0000950170-25-027864.md) | [178](/filings/0000950170-24-055832.md) | [217](/filings/0000950170-24-088661.md) | [261](/filings/0000950170-24-122375.md) | [305](/filings/0001193125-26-071776.md) | [319](/filings/0000950170-25-065765.md) | [398](/filings/0000950170-25-104126.md) | [477](/filings/0001193125-25-267040.md) | [551](/filings/0001193125-26-335235.md) | [603](/filings/0001193125-26-209110.md) | [570](/filings/0001193125-26-335235.md) |
| Current assets | $m | [305](/filings/0000950170-23-057530.md) | [344](/filings/0000950170-25-027864.md) | [311](/filings/0000950170-24-055832.md) | [358](/filings/0000950170-24-088661.md) | [401](/filings/0000950170-24-122375.md) | [554](/filings/0001193125-26-071776.md) | [582](/filings/0000950170-25-065765.md) | [652](/filings/0000950170-25-104126.md) | [685](/filings/0001193125-25-267040.md) | [728](/filings/0001193125-26-335235.md) | [773](/filings/0001193125-26-209110.md) | [753](/filings/0001193125-26-335235.md) |
| Total assets | $m | [1,188](/filings/0000950170-23-057530.md) | [1,244](/filings/0000950170-25-027864.md) | [1,268](/filings/0000950170-24-055832.md) | [1,225](/filings/0000950170-24-088661.md) | [1,232](/filings/0000950170-24-122375.md) | [1,301](/filings/0001193125-26-071776.md) | [1,254](/filings/0000950170-25-065765.md) | [1,334](/filings/0000950170-25-104126.md) | [1,429](/filings/0001193125-25-267040.md) | [1,635](/filings/0001193125-26-335235.md) | [1,837](/filings/0001193125-26-209110.md) | [1,703](/filings/0001193125-26-335235.md) |
| Current liabilities | $m | [36.2](/filings/0000950170-23-057530.md) | [38.1](/filings/0000950170-25-027864.md) | [29.9](/filings/0000950170-24-055832.md) | [28.2](/filings/0000950170-24-088661.md) | [224](/filings/0000950170-24-122375.md) | [236](/filings/0001193125-26-071776.md) | [235](/filings/0000950170-25-065765.md) | [247](/filings/0000950170-25-104126.md) | [48.5](/filings/0001193125-25-267040.md) | [49.7](/filings/0001193125-26-335235.md) | [36.6](/filings/0001193125-26-209110.md) | [47.1](/filings/0001193125-26-335235.md) |
| Long-term debt | $m | [446](/filings/0000950170-23-057530.md) | [446](/filings/0000950170-25-027864.md) | [447](/filings/0000950170-24-055832.md) | [447](/filings/0000950170-24-088661.md) | [256](/filings/0000950170-24-122375.md) | [256](/filings/0001193125-26-071776.md) | [257](/filings/0000950170-25-065765.md) | [257](/filings/0000950170-25-104126.md) | [257](/filings/0001193125-25-267040.md) | [258](/filings/0001193125-26-335235.md) | [258](/filings/0001193125-26-209110.md) | [258](/filings/0001193125-26-335235.md) |
| Current portion of debt | $m | [0.0](/filings/0000950170-23-057530.md) | [0.0](/filings/0000950170-25-027864.md) | not reported | not reported | [192](/filings/0000950170-24-122375.md) | [192](/filings/0001193125-26-071776.md) | [192](/filings/0000950170-25-065765.md) | [192](/filings/0000950170-25-104126.md) | [0.0](/filings/0001193125-25-267040.md) | [0.0](/filings/0001193125-26-071776.md) | not reported | not reported |
| Shareholders' equity | $m | [627](/filings/0000950170-24-122375.md) | [675](/filings/0001193125-26-071776.md) | [704](/filings/0001193125-25-267040.md) | [666](/filings/0001193125-25-267040.md) | [669](/filings/0001193125-25-267040.md) | [691](/filings/0001193125-26-071776.md) | [647](/filings/0001193125-26-335235.md) | [715](/filings/0001193125-26-335235.md) | [1,010](/filings/0001193125-25-267040.md) | [1,173](/filings/0001193125-26-335235.md) | [1,342](/filings/0001193125-26-209110.md) | [1,233](/filings/0001193125-26-335235.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:DebtCurrent
- Shareholders' equity: us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest, us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [43.9 d](/filings/0000950170-24-122375.md) | [33.3 d](/filings/0001193125-26-071776.md) | [37.0](/filings/0000950170-25-065765.md) | [43.7 d](/filings/0000950170-25-104126.md) | [48.7 d](/filings/0001193125-25-267040.md) | [59.2 d](/filings/0001193125-26-071776.md) | [48.6](/filings/0001193125-26-209110.md) | [44.1 d](/filings/0001193125-26-335235.md) | [49.7 d](/filings/0001193125-25-267040.md) | [54.5 d](/filings/0001193125-26-071776.md) | [35.3](/filings/0001193125-26-209110.md) | [52.0 d](/filings/0001193125-26-335235.md) |
| Capital expenditure | $m | [0.2 d](/filings/0000950170-24-122375.md) | [0.2 d](/filings/0001193125-26-071776.md) | [0.0](/filings/0000950170-24-055832.md) | [0.0 d](/filings/0000950170-24-088661.md) | [0.3 d](/filings/0001193125-25-267040.md) | [0.0 d](/filings/0001193125-26-071776.md) | [0.0](/filings/0001193125-26-209110.md) | [0.0 d](/filings/0001193125-26-335235.md) | [1.1 d](/filings/0001193125-25-267040.md) | [0.0 d](/filings/0001193125-26-071776.md) | [0.5](/filings/0001193125-26-209110.md) | [0.4 d](/filings/0001193125-26-335235.md) |
| Dividends paid | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Share repurchases | $m | [11.1 d](/filings/0000950170-24-122375.md) | [14.6 d](/filings/0001193125-26-071776.md) | [9.6](/filings/0000950170-25-065765.md) | [5.2 d](/filings/0000950170-25-104126.md) | [0.0 d](/filings/0001193125-25-267040.md) | [0.0 d](/filings/0001193125-26-071776.md) | [0.0](/filings/0001193125-26-209110.md) | [0.0 d](/filings/0001193125-26-335235.md) | [0.0 d](/filings/0001193125-25-267040.md) | [4.5 d](/filings/0001193125-26-071776.md) | [20.2](/filings/0001193125-26-209110.md) | [31.1 d](/filings/0001193125-26-335235.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Dividends paid: not reported
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [95.8](/filings/0000950170-23-057530.md) | [89.8](/filings/0000950170-24-055832.md) | [65.5](/filings/0000950170-24-088661.md) | [86.2](/filings/0000950170-24-122375.md) | [84.5](/filings/0000950170-25-065765.md) | [62.5](/filings/0000950170-25-104126.md) | [63.0](/filings/0001193125-25-267040.md) | [62.7](/filings/0001193125-26-209110.md) | [84.5](/filings/0001193125-26-335235.md) | [85.0](/filings/0001193125-25-267040.md) | [84.8](/filings/0001193125-26-209110.md) | [73.4](/filings/0001193125-26-335235.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 72,245,485 at 2026-07-31, from the cover of the [10-Q filed 2026-08-05](/filings/0001193125-26-335235.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:32 ET. No prices; not investment advice.